Biotechnology
Creative Biolabs Advances Liposome Technology for Enhanced Drug Delivery
Creative Biolabs is pioneering liposome technology to improve drug delivery systems, offering innovative solutions for pharmaceutical industries and beyond.
Creative Biolabs Advances mRNA Therapeutics with Comprehensive Solutions
Creative Biolabs is enhancing the development of mRNA therapies, offering innovative solutions that address key challenges in stability, delivery, and scalability, pivotal for treatments ranging from HIV to cancer.
Lexaria Bioscience Corp. Achieves Global Patent Milestone with 50 Patents
Lexaria Bioscience Corp. has reached a significant milestone with 50 patents granted worldwide, including new patents for epilepsy treatment and sublingual nicotine delivery, marking a pivotal moment in the company's strategy to expand its drug delivery platform.
Creative Biolabs Expands Skincare Innovation with Multi-source Exosome Research Line
Creative Biolabs introduces a groundbreaking multi-source exosome skincare research line, offering new avenues for anti-aging and regenerative skincare solutions.
Nutriband Inc. Secures U.S. Patent for AVERSA(TM) Technology, Aiming to Curb Drug Abuse
Nutriband Inc.'s new U.S. patent for its AVERSA(TM) technology marks a significant step forward in preventing the misuse and abuse of transdermal drugs, addressing a critical aspect of the ongoing opioid crisis.
Nuvectis Pharma Attracts Significant Insider Investment Amid Promising Oncology Pipeline
Nuvectis Pharma's strategic insider buying and advanced oncology pipeline position it as a potential breakout biotech in 2025.
Annovis Bio Inc. Secures 18-Month NYSE Compliance Extension
Annovis Bio Inc. (NYSE: ANVS) has been granted an 18-month period by the NYSE to meet listing requirements, ensuring continued trading of its shares while it advances therapies for neurodegenerative diseases.
Scientific Breakthrough in Anti-Aging: Key Ingredients Show Promise
Recent dermatological research highlights five key ingredients—Matrixyl, Argireline, Volufiline, Retinol, and PDRN—that offer significant anti-aging benefits, addressing wrinkles, skin volume loss, and cellular senescence with minimal irritation.
Creative Biolabs' Cell Line Innovations Propel Antibody Therapy Advancements
Creative Biolabs' latest developments in cell line technology are revolutionizing antibody therapy, offering new hope for cancer treatment and biotech research.
Quantum BioPharma Ltd. Advances in Brain and Alcohol Health Research with Phase 2 Trial Approval
Quantum BioPharma Ltd. makes significant strides in its brain disorders and alcohol health pipeline, including Phase 2 trial approval for FSD202 and preparations for an IND filing for Lucid-MS, highlighting its commitment to addressing unmet medical needs.
BiomX Inc. Achieves Breakthrough in Treating Antibiotic-Resistant Infections
BiomX Inc. has reported successful Phase 2 clinical trial results for treating diabetic foot bone infections and cystic fibrosis with bacteriophage therapy, offering a potential solution to the growing antibiotic resistance crisis.
Jupiter Neurosciences' Dual Strategy Paves Way for Biotech Innovation and Revenue Stability
Jupiter Neurosciences Inc. combines clinical drug development with a direct-to-consumer product line to address neuroinflammation and rare diseases, ensuring both long-term impact and short-term revenue amidst industry challenges.
GeoVax Gains EMA Support for Streamlined Mpox and Smallpox Vaccine Development
GeoVax Labs, Inc. receives favorable regulatory guidance from the European Medicines Agency, simplifying the development pathway for its GEO-MVA vaccine against Mpox and smallpox, marking a significant step towards addressing global vaccine shortages.
Creative Biolabs Enhances Non-IgG Antibody Development with Innovative Platform
Creative Biolabs introduces a groundbreaking platform for the development of non-IgG antibodies, addressing key challenges in yield, purification, and stability to unlock their therapeutic potential.
Utah's Life Sciences Sector Shines at BIO International Convention
BioUtah and partners showcase Utah's rapidly growing life sciences industry at the BIO International Convention, highlighting the state's collaborative ecosystem and business-friendly environment.
Content Carnivores LLC to Showcase Global Life Sciences Innovations at BIO International Convention 2025
Content Carnivores LLC will participate in the BIO International Convention 2025, representing innovative life sciences companies from North America and Europe, highlighting Utah's growing life sciences sector and facilitating global partnerships.
Soligenix Inc. Advances Clinical Programs with Key Trial Results Expected by 2026
Soligenix Inc. is making significant progress in its clinical programs, with critical trial results for treatments of rare diseases like cutaneous T-cell lymphoma and Behçet’s disease expected in the coming years, highlighting the company's role in addressing unmet medical needs.
Scinai Immunotherapeutics Ltd. Showcases Strategic Milestones and Funding Ahead of BIO 2025
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) prepares for the BIO International Convention 2025, highlighting its CDMO business growth and nanobody pipeline progress, alongside securing $1.38 million in funding to support its operations without additional dilution.
GeoVax to Showcase Innovative Vaccines and Therapies at BIO International Convention 2025
GeoVax Labs, Inc. announces its participation in the 2025 BIO International Convention, highlighting its pipeline of vaccines and immunotherapies for infectious diseases and cancer, underscoring the company's role in advancing global health solutions.
Lantern Pharma Advances Precision Oncology with AI-Driven Platform
Lantern Pharma Inc. leverages its AI-driven RADR(R) platform to accelerate the development of precision cancer therapies, with three lead drug candidates in clinical trials and multiple FDA designations enhancing its regulatory pathways.
GeoVax Advances Mpox Vaccine Development Amid WHO's Global Health Emergency Declaration
GeoVax Labs, Inc. is responding to the WHO's declaration of Mpox as a global public health emergency by advancing its GEO-MVA vaccine, aiming to address the urgent need for diversified vaccine supply and enhanced pandemic preparedness.
Calidi Biotherapeutics Appoints Biotech Veteran Eric Poma as CEO to Drive Growth
Calidi Biotherapeutics Inc. has named Eric Poma, PhD, as its new CEO and board member, marking a strategic step to advance its innovative cancer therapies towards commercialization.
Tonix Pharmaceuticals to Showcase Innovations at 2025 BIO International Convention
Tonix Pharmaceuticals Holding Corp. is set to present at the 2025 BIO International Convention, highlighting its advancements in pain management and public health solutions, including a potential new treatment for fibromyalgia.
Medicus Pharma Ltd. (NASDAQ: MDCX) Strategically Positions Itself in the Rapidly Growing $5 Trillion Biotech Market
Medicus Pharma Ltd. is leveraging the aging global population and technological advancements in biopharma to address chronic diseases, positioning itself for significant growth in the $5 trillion biotech market by 2034.
Oragenics Inc. to Showcase Concussion Treatment Candidate at Major 2025 Biotech and Neurotrauma Events
Oragenics Inc. (NYSE American: OGEN) is set to present its intranasal neurosteroid candidate for concussion treatment, ONP-002, at two significant 2025 events, highlighting its potential impact on neurology and pharmaceutical sectors.
Tevard Biosciences Appoints Dr. Elisabeth Gardiner as Chief Scientific Officer to Advance tRNA-Based Therapies
Tevard Biosciences has appointed Dr. Elisabeth Gardiner as its new Chief Scientific Officer, marking a significant step in advancing its tRNA-based therapies for genetic diseases, with implications for treating conditions like Duchenne Muscular Dystrophy and TTN-related dilated cardiomyopathy.
Alfa Cytology Launches PARP Inhibitors Development Services for Advanced Cancer Treatment
Alfa Cytology has introduced comprehensive development services for PARP inhibitors, offering a promising avenue for more precise and personalized cancer treatments, particularly for cancers with genetic mutations like BRCA1 and BRCA2.
Clene Inc. CEO to Present at Investor Summit Virtual, Highlighting Progress in Neurodegenerative Disease Treatment
Clene Inc.'s CEO Rob Etherington will update investors on the company's advancements in treating neurodegenerative diseases at the Investor Summit Virtual, showcasing potential breakthroughs in mitochondrial health and neuronal protection.
ABVC BioPharma's Affiliate OncoX Acquires Lycopenoid Platform, Bolstering Oncology Portfolio
OncoX BioPharma Inc., an affiliate of ABVC BioPharma, has acquired the Lycopenoid Lycogen® platform, a move that could generate significant revenue through a scalable royalty strategy and strengthen ABVC's position in botanical oncology innovation.
Kamada Intensifies Efforts to Highlight CYTOGAM's Role in CMV Management for Transplant Patients
Kamada Ltd. is amplifying its commitment to organ transplant patients by enhancing awareness and research around CYTOGAM, its treatment for cytomegalovirus (CMV), a potentially deadly complication for transplant recipients.